Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-PSCA CAR-T cell therapy - City of Hope National Medical Center/Mustang Bio

Next Previous
Drug Profile

Anti-PSCA CAR-T cell therapy - City of Hope National Medical Center/Mustang Bio

Alternative Names: Anti prostate stem cell antigen-CAR-T cell therapy - City of Hope Medical Center/Mustang Bio; Autologous Anti-PSCA(dCH2)BBz-CAR T-cells; Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-cells; CAR-T cells - Mustang Bio; MB 105; MB-105 PSCA CAR; PSCA(dCH2)BBzeta-CAR T-cells; PSCA‐targeted CAR T cell therapy

Latest Information Update: 17 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator City of Hope National Medical Center
  • Developer City of Hope National Medical Center; Mustang Bio
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Bladder cancer; Gastric cancer; Glioblastoma; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 13 Jun 2024 Adverse events data from a phase I trial in Prostate cancer released by City of Hope National Medical Center
  • 12 Jun 2024 Efficacy and adverse events data from a phase I trial in Prostate cancer were released by City of Hope National Medical Center
  • 28 Mar 2024 Discontinued - Phase-I for Pancreatic cancer in USA (IV)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top